UK Regulator Puts Energies Into COVID-19 While Other Services May Take Longer
Executive Summary
With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.
You may also be interested in...
UK Shares How Its Medtech Regs Already Diverge From The EU: COVID-19 Marks The Start
The MHRA has updated its guidance on regulatory flexibilities for medical devices and medicinal products resulting from COVID-19 to highlight how its approach differs from the EU.
UK Allows Non-CE-Marked Devices On Market Under Exceptional Use Route
The UK government has launched an initiative to get non-medtech manufacturers involved in the production of ventilators. But it looks like they will be scrapped after the emergency has passed.
How And Where Tougher Clinical Evaluation Measures Under EU MDR Cause Challenges
A first of its kind study examines how large compared with medium companies are coping with the EU’s strict clinical evidence requirements. The results show how it is the more stringent demands for high-risk devices that are leading to device removals as well as market launch outside the EU.